Microbiota Transplant Therapy (MTT) Improves Gastrointestinal Symptoms in Children with Pitt-Hopkins Syndrome: A Randomized Clinical Trial

Technical Summary: Microbiota Transplant Therapy (MTT) in Pitt-Hopkins Syndrome

Problem Statement
Pitt-Hopkins syndrome (PTHS) is an ultra-rare, monogenic neurodevelopmental disorder caused by pathogenic variants in the TCF4 gene. While characterized by severe cognitive and motor impairments, PTHS is also frequently accompanied by debilitating gastrointestinal (GI) dysfunction, including chronic constipation, abdominal pain, and distension. These GI symptoms often dominate clinical management and are cited by caregivers as the primary driver of behavioral outbursts. Despite the known co-occurrence of genetic defects and GI dysfunction, no interventional clinical trials had previously been conducted in this population to test whether modulating the gut ecosystem could alleviate symptoms. The study addresses the hypothesis that microbiome-targeted interventions, specifically Microbiota Transplant Therapy (MTT), can modify clinically meaningful outcomes in this genetically defined disorder, leveraging PTHS as a stringent model for gut-brain axis research.

Methodology
The study was a randomized, double-blind, placebo-controlled trial (RCT) with an open-label extension, registered at ClinicalTrials.gov (NCT04132427).

• Participants: Seven children with PTHS were initially screened; six completed all study phases (mean age 12.9 years). Due to the ultra-rare nature of the condition and the requirement to swallow capsules, the sample size was constrained. Participants were randomized 1:1 into Group A (active treatment first) and Group B (placebo first).
• Intervention: The active treatment (MTT) consisted of:
  1. 10 days of oral vancomycin (40 mg/kg/day) to deplete native microbiota.
  2. One day of bowel cleansing with magnesium citrate.
  3. A loading dose of MTP-101C (5 × 10¹¹ cells/day) for 4 days.
  4. 12 weeks of maintenance therapy (1 × 10¹¹ cells/day) via oral encapsulated donor microbiota derived from a screened healthy adult.
  • The placebo group received identical regimens with vancomycin/placebo capsules and sterile trehalose/carboxymethylcellulose capsules.
• Study Design:
  • Part 1 (Blinded): 14 weeks of intervention.
  • Part 2 (Open-label): Group B crossed over to active treatment; Group A entered an observation period.
  • Part 3: Both groups underwent 14 weeks of post-treatment observation.
• Assessments:
  • Primary Outcome: Daily Stool Record (DSR), a composite measure of abnormal stool days (Bristol Stool Form Scale types 1–2 and 6–7), medication use, and abdominal pain.
  • Secondary Outcomes: Gastrointestinal Symptom Rating Scale (GSRS), FLACC pain scale, Parent Global Impressions (PGI), and Clinical Global Impressions (CGI).
  • Biosamples: Fecal samples were collected for shotgun metagenomics, 16S rRNA amplicon sequencing, fungal ITS sequencing, and short-chain fatty acid (SCFA) quantification. Buccal swabs were analyzed for mitochondrial Complex IV activity.
• Statistical Analysis: Given the small sample size (n=6), the study relied heavily on Cohen's d effect sizes and one-tailed t-tests/Wilcoxon signed-rank tests. Multiple hypothesis testing correction was generally not applied due to the exploratory nature of the trial, except for gene abundance data.

Key Results

• Clinical Efficacy: MTT produced substantial and durable improvements in GI symptoms.
  • The primary outcome (DSR Total Events) decreased by 38% in the treatment group versus 1% in the placebo group during the blinded phase (Cohen's d = 1.3).
  • Secondary outcomes showed large effect sizes: GSRS scores decreased by 80% (active) vs. 31% (placebo); FLACC pain scores decreased by 71% (active) vs. 47% (placebo).
  • Improvements were sustained through the 3–6 month follow-up, with pooled post-treatment data showing a Cohen's d of 0.85 to 1.89 depending on the metric.
  • Behavioral improvements (mood, irritability, sociability) were reported by parents and clinicians, correlating with GI relief.
• Safety: The therapy was well-tolerated with no serious adverse events. Transient side effects included flatulence and mild diarrhea, which resolved without intervention.
• Microbiome Remodeling:
  • Engraftment: SourceTracker analysis indicated 25–28% donor engraftment that persisted at the 3-month follow-up.
  • Taxonomic Shifts: Treatment significantly increased Bifidobacterium bifidum (rising from near absence to levels exceeding typically developing controls) and decreased Enterocloster bolteae (a taxa enriched in PTHS at baseline).
  • Metabolites: Fecal butyrate concentrations increased significantly post-treatment and remained elevated at follow-up. Acetate and propionate levels remained unchanged.
  • Fungal Microbiome: Unlike bacteria, the fungal microbiome (including Candida albicans) showed minimal change following MTT.
• Mitochondrial Function: Baseline buccal mitochondrial Complex IV activity was significantly reduced (46% of typically developing controls). Following MTT, Complex IV activity increased by 26% in the treatment group during the blinded phase, with further improvements (reaching ~68% of control levels) after crossover.
• Correlations: Exploratory multi-omics analysis suggested associations between specific microbial shifts (e.g., Akkermansia, Roseburia, Bacteroides uniformis) and improvements in abdominal pain, stool frequency, and indigestion at different timepoints.

Significance and Claims
The paper claims to provide the first randomized, placebo-controlled evidence that microbiome-directed therapy can produce clinically meaningful and durable improvements in a monogenic neurodevelopmental disorder. The authors posit that:

1. Therapeutic Modifiability: Despite the genetic etiology of PTHS (TCF4 mutation), downstream physiological features such as GI dysfunction and altered host metabolism remain modifiable via the gut microbiome.
2. Gut-Brain-Mitochondria Axis: The observed partial normalization of mitochondrial Complex IV activity suggests a link between microbiome restructuring, metabolite availability (specifically butyrate), and host bioenergetics. This supports a model where microbial metabolites influence mitochondrial function and redox balance.
3. Model for Rare Diseases: PTHS serves as a rigorous model for testing causal contributions of the gut microbiome to neurodevelopmental phenotypes, suggesting that microbiome-targeted interventions may have therapeutic relevance even in disorders with defined genetic causes.

The authors explicitly state that due to the small sample size, the findings are preliminary and hypothesis-generating rather than confirmatory. They emphasize the need for larger, mechanistically focused studies to validate these results and identify biomarkers of response. The study concludes that MTT is safe and effective for improving GI symptoms in PTHS, with potential secondary benefits for behavior and mitochondrial function.